Theriva Biologics, Inc. (TOVX) Free cash flow 2016–2025
Theriva Biologics, Inc. (TOVX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$16.7MFY2025 · since FY2016: -$28.5M → -$16.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$16.7M | +1.4% |
| FY2024 | -$16.9M | +11.8% |
| FY2023 | -$19.2M | +0.0% |
| FY2022 | -$19.2M | -48.8% |
| FY2021 | -$12.9M | -6.0% |
| FY2020 | -$12.2M | +12.2% |
| FY2019 | -$13.9M | +19.7% |
| FY2018 | -$17.3M | +15.3% |
| FY2017 | -$20.4M | +28.3% |
| FY2016 | -$28.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TOVX financial trends
TOVX RevenueTOVX Net incomeTOVX Net marginTOVX Gross profitTOVX Gross marginTOVX Operating incomeTOVX Operating marginTOVX Operating cash flowTOVX Capital expendituresTOVX Return on equityTOVX Stock buybacksTOVX Dividends paidTOVX Total assetsTOVX Total liabilitiesTOVX Shareholders’ equityTOVX overview →